Clinical impact of circulating miR-133, miR-1291 and miR-663b in plasma of patients with acute myocardial infarction

Abstract

BackgroundAcute myocardial infarction (AMI) is one of the leading causes for death in both developed and developing countries and it is the single largest cause of death in the United States, responsible for 1 out of every 6 deaths. The objective of this study was to determine microRNA (miRNA) expression in AMI and determine whether miR-133, miR-1291 and miR-663b could be measured in plasma as a biomarker for recurrence.MethodsPatients with AMI and those without AMI were retrospectively recruited for a comparison of their plasma miR-133, miR-1291 and miR-663b expression.ResultsmiR-133, miR-1291 and miR-663b levels were significantly overexpressed in AMI compared with Non-AMI. MiR-133 showed an AUC of 0.912, with a sensitivity of 81.1% and a specificity of 91.2%. The AUC for miR-1291 was 0.695, with a sensitivity of 78.4% and a specificity of 89.5%. The AUC for miR-663b was 0.611, with a sensitivity of 72.4% and a specificity of 76.5%.ConclusionsThis study demonstrated that the levels of miR-133, miR-1291 and miR-663b are associated with AMI. The potential of these miRNAs as biomarkers to improve patient stratification according to the risk of AMI and as circulating biomarkers for the AMI progonos warrants further study.Virtual SlidesThe virtual slide(s) for this article can be found here: http://www.diagnosticpathology.diagnomx.eu/vs/8183629061241474

Circulating microRNAs and sudden cardiac arrest outcomes

“…For example, miR-210 is widely expressed, mechanistically linked to several cellular targets, and thought to be sensitive to hypoxia in a variety of contexts 25 . Similarly, changes in expression of the cardiomyocyte-specific miRNAs we report above have been demonstrated in a number of cardiac diseases, including myocardial infarction and heart failure 26, 27 .…”

The Diagnostic Value of Mir-133a in ST Elevation and Non-ST Elevation Myocardial Infarction: A Meta-Analysis

“…The remaining 23 eligible studies [10][11][12][16][17][18][19][20][21][22][24][25][26][27][28][29][30][31][32][33][34][35][36] were thoroughly analyzed and subjected to the above inclusion criteria ultimately yielding 9 studies (Table 1) involving 2280 participants, with 943 AMI patients and 1337 controls that were included in the quantitative meta-analysis. AMI-acute myocardial infarction; STEMI-ST elevation myocardial infarction; NSTEMI-non-ST elevation myocardial infarction; AUC-area under the curve.…”

“…This is most likely the result of damaged myocardium releasing Mir-133a during cellular lysis, or adjacent border zone myocardium releasing Mir-133a containing vesicles in response to the cardiac insult [16]. The research on Mir-133a's diagnostic potential, however, is strongly conflicted, with some papers reporting weak correlations between circulating Mir-133a concentrations and AMI [10,17], and others reporting strong correlations with excellent sensitivity and specificity [11,[18][19][20][21][22]. In light of these contradictory findings, this meta-analysis synthesizes data from existing literature in order to examine the true potential of Mir-133a as a biomarker in AMI.…”

Bioinformatic screening for key miRNAs and genes associated with myocardial infarction

“…It is worth mentioning that HSPA6 and miR‐31* had a great diagnose value for MI. MiR‐1291 has been identified as a potential diagnosis biomarker for acute MI .…”

“…It is worth mentioning that HSPA6 and miR-31* had a great diagnose value for MI. MiR-1291 has been identified as a potential diagnosis biomarker for acute MI [49]. Clinically, HCM is defined in the presence of left ventricular hypertrophy in the absence of hypertension and valve disease.…”